Evidence map›Paper›PMID 24829690›Full record

ReviewMiddle East journal of digestive diseases2013

Liver transplantation for hepatocellular carcinoma: past, present and future.

Reza F Saidi, Seyed Kamran Hejazi Kenari

Abstract readReview
PubMed Full text at PMC
In one paragraph

Review in Middle East journal of digestive diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Reza F SaidiDivision of Transplantation, Department of Surgery, Alpert Medical School of Brown University, Providence, Rhode Island, USA.
Seyed Kamran Hejazi KenariDivision of Transplantation, Department of Surgery, Alpert Medical School of Brown University, Providence, Rhode Island, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) represents one of the most common neoplasmsworldwide. Liver trasnplantation (LT) is the treatment of choice forselected group of patients with HCC.LT is actually a consolidated therapeutic option for HCC because it cures bothtumor and underlying cirrhosis.In 1996, the publication of a pivotal prospective study on less than 50 patients,transplanted for HCC under predefined criteria (single HCC ≤ 5 cm or 3 HCC≤ 3 cm each), the so called "Milan criteria", showed a 4-year survival of 75%.However, the indication of LT for HCC treatment has evolved over recentyears. The possibility of an extension of Milan criteria as indication for LT is alreadya debated issue. Living donor LT (LDLT) is an alternative option if waiting list is long and offersthe possibility of a LT after a short time.In this review, the current indications and results of liver transplantion for HCChave been dsicusssed.

Indexed as

Down stagingHepatocellular carcinomaIndicationsLiver transplantationOutcomes

Identifiers

PMID24829690
PMCPMC3990154

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.